Market News AIOpen the app

Pasithea Therapeutics Corp.: Regulation FD Disclosure (KTTA)

TrialRead the original at SEC EDGAR
Good for KTTA

Pasithea reported a 41% median best reduction in target cutaneous tumor area across 15 participants, and the FDA cleared a Phase 2 trial. Plexiform findings are early, but the cutaneous results support a positive read.

KTTA · Pasithea Therapeutics Corp.

AI read · Good for KTTA

The AI's read

The cutaneous tumor results give Pasithea evidence to take PAS-004 into a larger study. The plexiform tumor findings are still early: only 2 of 18 participants had reductions of at least 20%. The study does not yet show whether the shrinkage will last or help a wider group.

Get alerts for KTTA

Follow Pasithea Therapeutics Corp. (KTTA) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for KTTA
Free on the App Store and Google Play, or on the web.